Literature DB >> 21346783

Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins.

Paula Martínez1, María A Blasco.   

Abstract

Mammalian telomeres are formed by tandem repeats of the TTAGGG sequence, which are progressively lost with each round of cell division. Telomere protection requires a minimal length of TTAGGG repeats to allow the binding of shelterin, which prevents the activation of a DNA damage response (DDR) at chromosome ends. Telomere elongation is carried out by telomerase. Telomerase can also act as a transcriptional modulator of the Wnt-β-catenin signalling pathway and has RNA-dependent RNA polymerase activity. Dysfunctional telomeres can lead to either cancer or ageing pathologies depending on the integrity of the DDR. This Review discusses the role of telomeric proteins in cancer and ageing through modulating telomere length and protection, as well as regulating gene expression by binding to non-telomeric sites.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21346783     DOI: 10.1038/nrc3025

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  195 in total

1.  p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis.

Authors:  L Chin; S E Artandi; Q Shen; A Tam; S L Lee; G J Gottlieb; C W Greider; R A DePinho
Journal:  Cell       Date:  1999-05-14       Impact factor: 41.582

2.  POT1b protects telomeres from end-to-end chromosomal fusions and aberrant homologous recombination.

Authors:  Hua He; Asha S Multani; Wilfredo Cosme-Blanco; Hidetoshi Tahara; Jin Ma; Sen Pathak; Yibin Deng; Sandy Chang
Journal:  EMBO J       Date:  2006-10-19       Impact factor: 11.598

3.  DNA methyltransferases control telomere length and telomere recombination in mammalian cells.

Authors:  Susana Gonzalo; Isabel Jaco; Mario F Fraga; Taiping Chen; En Li; Manel Esteller; María A Blasco
Journal:  Nat Cell Biol       Date:  2006-03-26       Impact factor: 28.824

4.  Mad2 overexpression promotes aneuploidy and tumorigenesis in mice.

Authors:  Rocío Sotillo; Eva Hernando; Elena Díaz-Rodríguez; Julie Teruya-Feldstein; Carlos Cordón-Cardo; Scott W Lowe; Robert Benezra
Journal:  Cancer Cell       Date:  2006-12-28       Impact factor: 31.743

5.  Telomerase-deficient mice with short telomeres are resistant to skin tumorigenesis.

Authors:  E González-Suárez; E Samper; J M Flores; M A Blasco
Journal:  Nat Genet       Date:  2000-09       Impact factor: 38.330

6.  Structure of human POT1 bound to telomeric single-stranded DNA provides a model for chromosome end-protection.

Authors:  Ming Lei; Elaine R Podell; Thomas R Cech
Journal:  Nat Struct Mol Biol       Date:  2004-11-21       Impact factor: 15.369

7.  Transient activation of beta-catenin signalling in adult mouse epidermis is sufficient to induce new hair follicles but continuous activation is required to maintain hair follicle tumours.

Authors:  Cristina Lo Celso; David M Prowse; Fiona M Watt
Journal:  Development       Date:  2004-04       Impact factor: 6.868

Review 8.  Evolving views of telomerase and cancer.

Authors:  Maria A Blasco; William C Hahn
Journal:  Trends Cell Biol       Date:  2003-06       Impact factor: 20.808

Review 9.  Telomerase and cancer therapeutics.

Authors:  Calvin B Harley
Journal:  Nat Rev Cancer       Date:  2008-03       Impact factor: 60.716

10.  A p53-dependent response limits epidermal stem cell functionality and organismal size in mice with short telomeres.

Authors:  Ignacio Flores; Maria A Blasco
Journal:  PLoS One       Date:  2009-03-19       Impact factor: 3.240

View more
  206 in total

1.  In silico evaluation of TERT inhibition by anticancer drugs.

Authors:  Porika Mahendar; Kalam Sirisha; Umasankar Kulandaivelu; Prakhya Laxmi Jaya Shankar; Tippani Radhika; Abbagani Sadanandam
Journal:  J Mol Model       Date:  2012-06-06       Impact factor: 1.810

2.  Adapting to life at the end of the line: How Drosophila telomeric retrotransposons cope with their job.

Authors:  Mary-Lou Pardue; Pg Debaryshe
Journal:  Mob Genet Elements       Date:  2011-07-01

3.  Telomere proteins POT1, TRF1 and TRF2 augment long-patch base excision repair in vitro.

Authors:  Adam S Miller; Lata Balakrishnan; Noah A Buncher; Patricia L Opresko; Robert A Bambara
Journal:  Cell Cycle       Date:  2012-03-01       Impact factor: 4.534

4.  PinX1 localizes to telomeres and stabilizes TRF1 at mitosis.

Authors:  Tohru Yonekawa; Shuqun Yang; Christopher M Counter
Journal:  Mol Cell Biol       Date:  2012-02-13       Impact factor: 4.272

5.  Signalling the end of the line.

Authors:  John van Tuyn; Peter D Adams
Journal:  Nat Cell Biol       Date:  2012-04-02       Impact factor: 28.824

Review 6.  Assessing cell and organ senescence biomarkers.

Authors:  Bruno Bernardes de Jesus; Maria A Blasco
Journal:  Circ Res       Date:  2012-06-22       Impact factor: 17.367

Review 7.  The role of telomeres and telomerase reverse transcriptase isoforms in pluripotency induction and maintenance.

Authors:  Jonathan H Teichroeb; Joohwan Kim; Dean H Betts
Journal:  RNA Biol       Date:  2016-01-19       Impact factor: 4.652

8.  IL-7Rα deficiency in p53null mice exacerbates thymocyte telomere erosion and lymphomagenesis.

Authors:  R Kibe; S Zhang; D Guo; L Marrero; F Tsien; P Rodriguez; S Khan; A Zieske; J Huang; W Li; S K Durum; T Iwakuma; Y Cui
Journal:  Cell Death Differ       Date:  2012-01-27       Impact factor: 15.828

9.  Non-canonical NF-κB signalling and ETS1/2 cooperatively drive C250T mutant TERT promoter activation.

Authors:  Yinghui Li; Qi-Ling Zhou; Wenjie Sun; Prashant Chandrasekharan; Hui Shan Cheng; Zhe Ying; Manikandan Lakshmanan; Anandhkumar Raju; Daniel G Tenen; Shi-Yuan Cheng; Kai-Hsiang Chuang; Jun Li; Shyam Prabhakar; Mengfeng Li; Vinay Tergaonkar
Journal:  Nat Cell Biol       Date:  2015-09-21       Impact factor: 28.824

Review 10.  Revisiting the hallmarks of cancer.

Authors:  Yousef Ahmed Fouad; Carmen Aanei
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.